Tafamidis's price sits ~85–95% above ICER's benchmark, but the orphan-drug exclusion keeps it out of IRA negotiation — so acoramidis competition and pending generics, not Medicare, drive ATTR-CM net price.
Tafamidis (Vyndaqel/Vyndamax) carries an annual US list price near $268,000, and ICER's October 2024 ATTR-CM review judged the TTR-stabilizer class priced roughly 85–95% above a cost-effective level: a value-based benchmark of about $13,600–$39,000 per year. Yet despite Medicare spend among the highest in any rare-disease category, tafamidis is not subject to CMS Inflation Reduction Act drug-price negotiation: it is absent from the first three negotiation cycles (IPAY 2026–2028), shielded by the orphan-drug exclusion that the 2025 tax-and-spending law broadened to protect drugs carrying multiple orphan designations — a protection that covers the ATTR stabilizer and silencer set.
With IRA negotiation off the table, competition sets net price. Acoramidis (Attruby, BridgeBio) launched in November 2024 roughly below tafamidis list, giving payers two-stabilizer leverage to negotiate deeper rebates on a shared Part D tier and to consider step-edits or therapeutic interchange; pending generic tafamidis adds further compression. Benefit routing splits the market: the oral stabilizers (tafamidis, acoramidis) run through Medicare Part D (where the IRA's $2,000 annual out-of-pocket cap now helps patients) while the infused or injected RNA silencers (patisiran, vutrisiran) run through the Part B medical benefit. Prior authorisation anchors on confirmed ATTR-CM, typically Tc-PYP scintigraphy (Gillmore grade 2–3) with a monoclonal protein excluded.
US ATTR agent payer status — 2026
| Drug (Brand / INN) | Benefit Routing | IRA Exposure | ICER Status | PA Criteria (Commercial) | Key Payer Risk |
|---|---|---|---|---|---|
| Vyndaqel / Vyndamax (tafamidis) | Medicare Part D (oral) | Not IRA-selected (orphan-drug exclusion; absent IPAY 2026–2028) | ~85–95% above ICER benchmark (ICER 2024) | Confirmed ATTR-CM (Tc-PYP grade 2–3 or biopsy); NYHA I–III | Acoramidis rebate pressure and pending generic tafamidis |
| Attruby (acoramidis) | Medicare Part D (oral) | Not IRA-selected; launched Nov 2024 below tafamidis | Included in ICER 2024 stabilizer-class review | Same ATTR-CM criteria; step-edit / therapeutic-interchange risk vs tafamidis | Two-stabilizer rebate contest; interchange positioning |
| Amvuttra (vutrisiran) | Medicare Part B (SC administered) | Not IRA-selected | ICER 2024 (ATTR-CM); ICER 2018 (ATTR-PN) | ATTR-CM approved Mar 2025; also hereditary ATTR-PN | Part B routing; SC dosing vs IV patisiran |
| Onpattro (patisiran) | Medicare Part B (IV infused) | Not IRA-selected | ICER ATTR-PN 2018 — value below WAC | Confirmed hereditary ATTR-PN; functional-impairment threshold | Site-of-care infusion cost; displacement by SC vutrisiran |
Sources: CMS selected-drug fact sheets (IPAY 2026–2028 — tafamidis not selected); ICER October 2024 ATTR-CM Final Evidence Report; ICER 2018 ATTR-PN review; FDA Drugs@FDA; BridgeBio (acoramidis approval, Nov 2024); HELIOS-B, NEJM 2025 (PMID 39213194).
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Tafamidis's absence from IPAY 2026–2028 and the orphan-drug exclusion (broadened 2025)
- why the whole ATTR class is shielded
- and how pricing pressure shifts onto acoramidis competition and pending generics rather than Medicare negotiation
Delivers
- Two-stabilizer rebate dynamics
- therapeutic-interchange and step-edit risk
- ATTRibute-CM clinical-differentiation argument as a counter to interchange
- acoramidis's below-tafamidis launch price
Delivers
- Part D (oral stabilizers, with the $2,000 IRA OOP cap) vs Part B (RNA silencers) OOP comparison
- commercial PA criteria and Tc-PYP diagnostic confirmation
- benefit-routing implications of vutrisiran's 2025 ATTR-CM approval
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- Why tafamidis's roughly $268,000 annual list price sits 85 to 95% above ICER's cost-effective benchmark.
- How Medicare Part D vs Part B routing splits oral stabilizers from infused RNA silencers across the ATTR class.
- Why tafamidis is absent from the first three IRA negotiation cycles, IPAY 2026 through 2028, under the orphan-drug exclusion.
- How the 2025 tax-and-spending law broadened this exclusion to shield drugs carrying multiple orphan designations.
- Why ICER's October 2024 ATTR-CM review set a value-based benchmark of about $13,600 to $39,000 per year.
- How this benchmark, far below tafamidis's list price, gives payers ammunition to demand steep rebates.
- Why acoramidis's November 2024 launch below tafamidis list price gave payers two-stabilizer rebate leverage.
- How step-edits, therapeutic interchange, and a pending generic tafamidis compound pricing pressure on the stabilizer class.
- Why oral stabilizers route through Medicare Part D, where the IRA's $2,000 annual out-of-pocket cap now applies.
- How infused or injected RNA silencers like patisiran and vutrisiran instead run through the Part B medical benefit.
- Why commercial payer PA anchors on confirmed ATTR-CM, typically established via Tc-PYP scintigraphy at Gillmore grade 2-3.
- How PA criteria require excluding a monoclonal protein before approving ATTR stabilizer or RNA-silencer therapy.
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
Every AXLRx assessment is built from primary regulatory sources (FDA Drugs@FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer and HTA documentation — not secondary summaries, market-research reports, or unverified estimates. Findings are independently verified before inclusion; if a figure cannot be sourced to a live record, it does not ship.
US ATTR Amyloidosis Payer & HTA sources: the CMS Medicare Drug Price Negotiation selected-drug fact sheets (confirming tafamidis's absence from IPAY 2026–2028 under the orphan-drug exclusion), the ICER October 2024 ATTR-CM Final Evidence Report and ICER's 2018 ATTR-PN review, FDA Drugs@FDA for approval status, and live commercial payer coverage and prior-authorisation policy documents.
- Tafamidis's exclusion from CMS IRA drug-price negotiation (orphan-drug exclusion; absent IPAY 2026–2028) verified against the CMS selected-drug fact sheets
- Tafamidis list price and the ~85–95%-above-benchmark cost-effectiveness finding verified against the ICER October 2024 ATTR-CM Final Evidence Report
- Acoramidis approval (Nov 2024) and vutrisiran's March 2025 ATTR-CM approval verified against FDA Drugs@FDA and BridgeBio
- Benefit routing (Part D oral stabilizers vs Part B RNA silencers) verified against CMS benefit classification
Frequently asked questions
Detailed analyses within this report
Commission this assessment
AXLRx ATTR Amyloidosis Payer & HTA is built for market access, HEOR, and pricing teams navigating IRA exposure, ICER positioning, and the Part D/Part B routing split in the US ATTR market. Custom assessment in 72 hours.
Specify indication, payer focus (IRA, ICER, PA criteria), and commercial question.
AXLRx analyst confirms payer scope, IRA timeline, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.